Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study

Código QR

Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study

Masahiro Takeshima,1 Hiroyasu Ishikawa,2 Takashi Kanbayashi,1 Tetsuo Shimizu3 1Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita City, Akita 010-8543, Japan; 2Department of Neuropsychiatry, Nakadori Rehabilitation Hospital, Akita City, Akita 010-0001, Japan; 3Akita...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takeshima M, Ishikawa H, Kanbayashi T, Shimizu T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	akathisia antipsychotic agents gabapentin enacarbil restless legs syndrome schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a604554dfb0043978cd326cd1be7799c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review
por: Kalniunas A, et al.
Publicado: (2021)

Gabapentin for once-daily treatment of post-herpetic neuralgia: a review
por: Beal B, et al.
Publicado: (2012)

Síndrome de piernas inquietas: Estudio clínico en población general adulta y en pacientes urémicos
por: Miranda C,Marcelo, et al.
Publicado: (2001)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

Alto subdiagnóstico del síndrome de piernas inquietas en la consulta ambulatoria neurológica y psiquiátrica
por: Miranda C,Marcelo, et al.
Publicado: (2009)

Hierro intravenoso en la terapia del síndrome de piernas inquietas
por: MIRANDA C.,MARCELO, et al.
Publicado: (2019)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward K, et al.
Publicado: (2019)

Electroconvulsive Therapy as a Corrector for Certain Side Effects of Antipsychotic Therapy
por: Yu. V. Bykov, et al.
Publicado: (2020)

DETERMINATION OF GABAPENTIN IN BULK DRUG AND IN PHARMACEUTICAL DOSAGE FORM BY HPLC METHOD
por: UDAYKUMAR RAO,B, et al.
Publicado: (2009)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Stephan Hjorth, et al.
Publicado: (2021)

Síndrome de Piernas Inquietas: Actualización Clínica
por: Miranda,Marcelo, et al.
Publicado: (2001)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Ping Yin, et al.
Publicado: (2021)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Prevalence of Restless Legs Syndrome and its Symptoms among Patients with Spinal Disorders
por: Hidetomi Terai, et al.
Publicado: (2021)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Tzu-Pei Yeh, et al.
Publicado: (2021)

Síndrome de piernas inquietas/Willis Ekbom desde la mirada del psiquiatra
por: Rubí G.,Patricia
Publicado: (2018)

Gabapentin enacarbil &ndash; clinical efficacy in restless legs syndrome
por: Pinky Agarwal, et al.
Publicado: (2010)

The prevalence of restless leg syndrome among pregnant Saudi women
por: Mohmd Khan, et al.
Publicado: (2018)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga S, et al.
Publicado: (2021)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications
por: Lei Chen, et al.
Publicado: (2021)

Restless legs syndrome: differential diagnosis and management with pramipexole
por: Francesca Brindani, et al.
Publicado: (2009)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang X, et al.
Publicado: (2019)

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
por: Patrick Köck, et al.
Publicado: (2021)

Drug Attitude, Insight, and Patient’s Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey
por: Nagai N, et al.
Publicado: (2020)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel T
Publicado: (2021)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi T, et al.
Publicado: (2017)

Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu C, et al.
Publicado: (2020)

Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
por: Fan L, et al.
Publicado: (2021)

Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study
por: Huang YC, et al.
Publicado: (2018)

Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
por: Bracha Erlanger Avigdor, et al.
Publicado: (2021)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini F, et al.
Publicado: (2019)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Effect of carbamazepine and gabapentin on excitability in the trigeminal subnucleus caudalis of neonatal rats using a voltage-sensitive dye imaging technique
por: Matsumoto,Akiko, et al.
Publicado: (2015)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
por: Ohnishi T, et al.
Publicado: (2021)

Effectiveness and Safety of Botulinum Toxin Type A in Treatment of Restless Legs Syndrome: A Systematic Review and Meta-Analysis
por: Yu-Chi Su, et al.
Publicado: (2021)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo M, et al.
Publicado: (2021)